Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPBWR1 | P48145 | 2/20 | 0.62 |
| ▸ | NPY2R | P49146 | 3/20 | 0.61 |
| ▸ | GHSR | Q92847 | 2/20 | 0.61 |
| ▸ | NPY4R | P50391 | 4/20 | 0.61 |
| ▸ | NPY1R | P25929 | 3/20 | 0.61 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.61 |
| ▸ | KISS1R | Q969F8 | 11/20 | 0.60 |
| ▸ | IL23R | Q5VWK5 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29883780 | 0.99 | NPBWR1 (0.62) | NPBWR1NPY2RGHSRNPY4RNPY1R | |
| SCHEMBL29641064 | 0.95 | NPBWR1 (0.66) | NPBWR1NPY2RGHSRNPY4RNPY1R | |
| SCHEMBL30092956 | 0.93 | NPBWR1 (0.65) | NPBWR1NPY2RNPY4RNPY1RNPY5R | |
| SCHEMBL30097937 | 0.92 | IL23R (0.63) | NPY2RGHSRIL23R | |
| SCHEMBL29486225 | 0.92 | GHSR (0.57) | NPBWR1NPY2RGHSRKISS1R | |
| SCHEMBL30093092 | 0.92 | NPBWR1 (0.65) | NPBWR1NPY2RGHSRNPY4RNPY1R | |
| SCHEMBL30092897 | 0.91 | NPBWR1 (0.68) | NPBWR1KISS1R | |
| SCHEMBL30093007 | 0.91 | NPBWR1 (0.69) | NPBWR1KISS1R | |
| SCHEMBL30093009 | 0.91 | NPBWR1 (0.69) | NPBWR1KISS1R | |
| SCHEMBL31696777 | 0.91 | IL23R (0.66) | NPBWR1IL23R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240108740-A1 | THERAPEUTIC COMPOSITIONS INCLUDING SPN10 AND USES THEREOF | STEALTH BIOTHERAPEUTICS INC. (US) | 2024-04-04 | — | — | US | disclosed |
| US-11931397-B2 | Methods and compositions for the treatment of Sengers syndrome | STEALTH BIOTHERAPEUTICS INC. (US) | 2024-03-19 | — | — | US | disclosed |
| US-20240059735-A1 | COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF MITOCHONDRIAL MYOPATHIES | STEALTH BIOTHERAPEUTICS INC. (US) | 2024-02-22 | — | — | US | disclosed |
| US-20230398172-A1 | METHODS FOR PREVENTION AND TREATMENT OF ACUTE RENAL INJURY | CORNELL UNIVERSITY (US) | 2023-12-14 | — | — | US | disclosed |
| US-20230201299-A1 | METHODS FOR THE PREVENTION AND TREATMENT OF BURN INJURIES AND SECONDARY COMPLICATIONS | THE GENERAL HOSPITAL CORPORATION D/B/A MASSACHUSETTS GENERAL HOSPITAL (US) | 2023-06-29 | — | — | US | disclosed |
| US-20230076067-A1 | MITOCHONDRIAL-TARGETED ANTIOXIDANTS PROTECT AGAINST MECHANICAL VENTILATION-INDUCED DIAPHRAGM DYSFUNCTION AND SKELETAL MUSCLE ATROPHY | CORNELL UNIVERSITY (US) | 2023-03-09 | — | — | US | disclosed |
| US-20220296671-A1 | METHODS FOR THE PREVENTION OR TREATMENT OF LEFT VENTRICLE REMODELING | STEALTH BIOTHERAPEUTICS INC. (US) | 2022-09-22 | — | — | US | disclosed |
| US-11266709-B2 | Methods for the regulation of matrix metalloproteinase expression | STEALTH BIOTHERAPEUTICS INC. (US) | 2022-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230076067-A1 | MITOCHONDRIAL-TARGETED ANTIOXIDANTS PROTECT AGAINST MECHANICAL VENTILATION-INDUCED DIAPHRAGM DYSFUNCTION AND SKELETAL MUSCLE ATROPHY | HSPA9, OPA1, ARG2 | NPBWR1 2410/4885NPY2R 3332/4885GHSR 3737/4885 |
| US-20230201299-A1 | METHODS FOR THE PREVENTION AND TREATMENT OF BURN INJURIES AND SECONDARY COMPLICATIONS | MUSK, TNNC1, TNNI3 | NPBWR1 383/4885NPY2R 476/4885GHSR 469/4885 |
| US-20230398172-A1 | METHODS FOR PREVENTION AND TREATMENT OF ACUTE RENAL INJURY | ARG2, SERPINC1, ARG1 | NPBWR1 521/4885NPY2R 431/4885GHSR 1450/4885 |
| US-20240059735-A1 | COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF MITOCHONDRIAL MYOPATHIES | MTPN, CKMT1A; CKMT1B, TFAM | NPBWR1 4014/4885NPY2R 3526/4885GHSR 4526/4885 |
| US-20240108740-A1 | THERAPEUTIC COMPOSITIONS INCLUDING SPN10 AND USES THEREOF | S100A10, SPG11, TMSB10 | NPBWR1 229/4885NPY2R 1797/4885GHSR 2407/4885 |
| US-20220296671-A1 | METHODS FOR THE PREVENTION OR TREATMENT OF LEFT VENTRICLE REMODELING | ARG2, TNNT2, MYLK2 | NPBWR1 515/4885NPY2R 313/4885GHSR 1557/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.